生物医药最常见的估值方法

业务成熟，收入增长稳定的Big Pharma (也包括CRO/ CDMO) 采用P/E估值法。

处于研发阶段，财务亏损的Biotech 创新药采用DCF或rNPV估值 (Nasdaq上市的biotech超过半数采用rNPV估值)。

产品处于导入期，尚未达到盈亏平衡的创新医疗器械则采用rNPV估值，并同时参考可比公司的 EV/Sales, EV/ EBITDA 和 P/S 市销率。

#绿叶制药

炒股技术派

炒股技术派聚集地，分享关于K线的财富密码~

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":340691457,"tweetId":"340691457","gmtCreate":1617389836079,"gmtModify":1617389836079,"author":{"id":3555021022728129,"idStr":"3555021022728129","authorId":3555021022728129,"authorIdStr":"3555021022728129","name":"爱丽小猪","avatar":"https://static.tigerbbs.com/8708aee15b9ac49f90b5324270a82a2d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[{"themeId":"8820d7d981fb49a1ba778e0c296ce85b","categoryId":"bc7f9e79615545918dda2e7d7cfb9e15","name":"炒股技术派","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":8820d7d981fb49a1ba778e0c296ce85b}&rnconfig={\"headerBarHidden\": true}","description":"炒股技术派聚集地，分享关于K线的财富密码~","image":"https://static.tigerbbs.com/0b2b3156e4e3c2045bf56c2a5c01e419"}],"images":[],"coverImages":[],"title":"生物医药最常见的估值方法","extraTitle":"","html":"<html><head></head><body><p>业务成熟，收入增长稳定的Big&nbsp;Pharma&nbsp;(也包括CRO/&nbsp;CDMO)&nbsp;采用P/E估值法。</p><p>处于研发阶段，财务亏损的Biotech&nbsp;创新药采用DCF或rNPV估值&nbsp;(Nasdaq上市的biotech超过半数采用rNPV估值)。</p><p>产品处于导入期，尚未达到盈亏平衡的创新医疗器械则采用rNPV估值，并同时参考可比公司的&nbsp;EV/Sales,&nbsp;EV/&nbsp;EBITDA&nbsp;和&nbsp;P/S&nbsp;市销率。</p><p>#绿叶制药</p></body></html>","htmlText":"<html><head></head><body><p>业务成熟，收入增长稳定的Big&nbsp;Pharma&nbsp;(也包括CRO/&nbsp;CDMO)&nbsp;采用P/E估值法。</p><p>处于研发阶段，财务亏损的Biotech&nbsp;创新药采用DCF或rNPV估值&nbsp;(Nasdaq上市的biotech超过半数采用rNPV估值)。</p><p>产品处于导入期，尚未达到盈亏平衡的创新医疗器械则采用rNPV估值，并同时参考可比公司的&nbsp;EV/Sales,&nbsp;EV/&nbsp;EBITDA&nbsp;和&nbsp;P/S&nbsp;市销率。</p><p>#绿叶制药</p></body></html>","text":"业务成熟，收入增长稳定的Big Pharma (也包括CRO/ CDMO) 采用P/E估值法。 处于研发阶段，财务亏损的Biotech 创新药采用DCF或rNPV估值 (Nasdaq上市的biotech超过半数采用rNPV估值)。 产品处于导入期，尚未达到盈亏平衡的创新医疗器械则采用rNPV估值，并同时参考可比公司的 EV/Sales, EV/ EBITDA 和 P/S 市销率。 #绿叶制药","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/340691457","repostId":0,"isVote":1,"tweetType":1,"viewCount":2483,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["399441","161726"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":276,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/340691457"}